BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28771725)

  • 1. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
    Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
    Sun NK; Huang SL; Lu HP; Chang TC; Chao CC
    Oncotarget; 2015 Sep; 6(29):27065-82. PubMed ID: 26318424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.
    Szajnik M; Szczepanski MJ; Czystowska M; Elishaev E; Mandapathil M; Nowak-Markwitz E; Spaczynski M; Whiteside TL
    Oncogene; 2009 Dec; 28(49):4353-63. PubMed ID: 19826413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
    Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
    Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
    Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
    Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
    Wang J; Ye C; Liu J; Hu Y
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
    Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
    Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
    Li Y; Sun J; Gao S; Hu H; Xie P
    Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
    Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
    Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
    Cheng G; Tian F; Li Y
    Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
    Tang J; Cao L; Yi H; Tang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.
    Su S; Sun X; Zhang Q; Zhang Z; Chen J
    Cell Struct Funct; 2019; 44(1):21-28. PubMed ID: 30760665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
    Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
    Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.